Objective: Rheumatoid arthritis is a common autoimmune disease for which there is no known cure. Ultraviolet light can induce immunosuppressive effects. Our main objective was to ascertain whether a complementary treatment with phototherapy improves changes in functional scales in patients with rheumatoid arthritis.
INTRODUCTION
Rheumatoid arthritis (RA) is a common autoimmune disease for which there is no known cure.
A diverse number of biological pathways are altered in patients with RA, which impinge on a wide-variety of cell types, tissue types and organ systems -innate immune cells (eg dendritic cells, mast cells, neutrophils, platelets), adaptive immune cells (eg B and T-cells), bone, cartilage, synovial fibroblasts, vascular cells, brain, muscle and fat (1) . The chronic manifestations of RA are primarily manifested in the synovial tissues, with symptoms of pain, stiffness, swelling, and progressive joint destruction (2) .
Drugs used for treatment can be divided into four broad categories: non-steroidal antiinflammatory drugs (NSAIDs), glucocorticoids, disease modifying antirheumatic drugs (DMARDs) and biologic agents. Since 2002, treatment recommendations for RA have suggested an aggressive approach to inhibit the progression of joint damage and other complications that may develop soon after diagnosis (3) (4) (5) . This aggressive approach includes initiation of DMARDs and biologic agents as soon as possible.
Among complementary alternatives to treat RA we find the use of light. In this respect, the frequency, wavelength and energy of an electromagnetic wave are related to one another with wavelength being inversely proportional to both frequency and energy. The huge spectrum of electromagnetic radiation can therefore be organized conceptually by decreasing wavelength into radio waves, microwaves, terahertz radiation, infrared radiation, visible light, ultraviolet (UV) radiation, X-rays and gamma rays.
Phototherapy is defined as the use of UV radiation in the treatment of skin disease. There are many types of phototherapy including: broadband UVB (280-320 nm), narrowband UVB (311-313 nm), UVA (340-400 nm), and combination therapy of psoralen plus UVA (PUVA).
Although UV light can induce strong inflammatory responses in susceptible individuals, under chronic or minimally erythematogenic doses its immunosuppressive effects are dominant.
The mechanism of this immunosuppression involves both cellular components and soluble mediators (6) . For example, Langerhans cells are very sensitive to UV radiation. These cells express molecules such as: MHC class II, lymphocyte function-associated antigen-3 (LFA-3), intercellular adhesion molecule (ICAM)-1, ICAM-3, B7, CD1a and CD40. Ultraviolet radiation induces these cells to migrate out of the skin to draining lymph nodes (7) (8) and there is a dramatic reduction in the previously mentioned markers following UV exposure (9).
Our main objective was to evaluate the changes in functional scales, biochemical and inflammatory variables in RA patients submitted to phototherapy within a range from 425 to 650 nm (visible light spectrum) and 11.33 Joules/cm 2 . An essential aspect of the study was the absolute respect to the management, evaluation and subsequent citations instituted by the treating rheumatologist. Only in cases where the patient was not receiving specialized care or that their problem was recently installed and did not have opportunity to apply this specialized care, we initiated the pharmacological management in conjunction with phototherapy.
METHODS

In
We obtained the general personal data from a medical history; anthropometry, biochemical evaluations and clinical scales to evaluate the RA affection were evaluated weekly.
Anthropometric measures were assessed in the Research Laboratory of the HMPMPS.
Body weight was measured in an overnight fasting status without shoes in a minimal clothing state by the use of a digital scale (Seca, Hamburg, Germany) to the nearest 0.1 kg. Height was measured using a non-stretched tape measure to the nearest 0.1 cm. Body mass index (BMI) was calculated as weight in kg divided by height in meters squared.
We Statistical analysis was performed using SPSS version 19. First, descriptive analyses were performed and then we compared if the group presented differences through the time by
Wilcoxon test. Difference was considered significant at p ≤ 0.05.
RESULTS
A total of seven patients, all women, media age of 44 years (range 21-56), with RA were enrolled for this study. Four patients were already in treatment with a Rheumatologist, and three were naïve to any kind of treatment.
The media of antirheumatic drugs that patients were taking at the moment of starting the protocol was of 2.2. The media of time within the protocol was of 140 ± 7.7 (SE) days and the media of prescribed phototherapy sessions was of 66 [range 34-77] ( Table 1) . The clinical characteristics of the studied women are showed in Table 2 . Table 3 shows the results of the evaluated scales. All the median scores were significantly better rated after the treatment period. Karnofsky changed from requiring frequent medical care to being capable of normal activity with few symptoms or signs of disease. The RaQol questionnaire decreased abruptly from 29 to cero points. Steinbrocker Functional Capacity Rating changed from limited to little or none of the duties of usual occupation or self-care to complete ability to carry out all the usual duties without handicaps. The pain was remitted after the treatment period.
The acute inflammation variables declined notoriously after the indicated sessions.
Erythrocyte sedimentation rate diminished more significantly than CRP although both reached a statistical difference. Metabolically speaking, albumin increased and cholesterol decreased after the survey.
DISCUSSION
There are many research lines searching for a better prognosis in RA. In spite of the great advances with the biological drugs, there is not still a cure and the cost of such therapy is not easily affordable for most of the patients. In this line of explorative options, there is scarce information related to the RA treatment with light exposure. In this respect, the described techniques are extracorporeal photochemotherapy (EPC), photodynamic therapy (PDT), photopheresis and UVA.
Extracorporeal photochemotherapy has been applied in refractory RA with clinical improvement, a decline in CRP and no adverse reactions recorded (11) . Photodynamic therapy is based on the use of light-sensitive molecules called photosensitizers. This photoactivation causes the formation of singlet oxygen, which produces peroxidative reactions that can cause cell damage and death (12) .
The use of photosensitizers is not a new topic in medicine (13) . Experimentally, incubation with chloroquine or methotrexate and subsequent laser irradiation at a wavelength of 351 nm resulted in an at least twenty-fold enhanced cytotoxicity. Both substances therefore may serve for a photodynamic therapy of rheumatoid arthritis (14) . We can not exclude the possibility of some patients being beneficiated under a photodynamic effect of either of both drugs. Our approach differs in many senses in relation to the above mentioned works. First, we used visible wavelength, which, to our knowledge is the first study demonstrating a clinical benefit in RA. In evaluating the clinical benefits with any treatment in RA patients the use of functional scales is mandatory. Our group has evaluated not one but five scales, all of them with evident demonstration of the successful in managing RA patients with phototherapy.
As it is well known, an objective way to probe the benefit of any treatment is the decreased in inflammatory variables. Our results showed a decrease in CRP and ESR. As an initial attempt we did not quantify TNF-α expression that has been included in a new protocol that has already begun.
A critical point to be considered is the role of vitamin D as its shortage in the diet added to a low sun light exposure could predispose to several diseases including RA (18) . In this respect, the fact that we use the 425 to 650 nm wavelength, could stimulate the vitamin D synthesis and as a consequence get a clinical benefit derived from this vitamin pathway. Whether phototherapy induces a clinical improvement by reducing oxidative stress, changing isomerization or any other molecular effect was beyond the scope of the present study.
This study has its limitations. The low number of cases does not give us enough power to extrapolate the results to a more diverse population. Also, it was not a randomized clinical trial as it was impossible to enroll enough naïve RA patients and successfully integrate comparative groups. This last attempt has to be developed in a Hospital with considerable RA incidence.
Despite the above mentioned limitation, our study has a strong point in reporting the results of five clinical scales and not only one.
Another point to be considered is the placebo effect. Without any doubt, this effect contributes to a feel of welfare but it would not be as definitely as has been documented using five different clinical scales. Moreover the placebo effect is conditioned by the personality (19), being extremely difficult that the seven patients had the same factors influencing placebo response. Finally, the mechanism that underlies the phototherapy has yet to be elucidated although there has been documentation of isomer changes and immunosuppression with this technique.
